Cite
HARVARD Citation
Steinberg, G. et al. (n.d.). A Phase I/II study of vesigenurtacel-l (hs-410) or placebo in combination with Bacillus Calmette-Guérin (BCG) in patients with non-muscle invasive bladder cancer (NMIBC). Journal for immunotherapy of cancer. p. . [Online].